TACONIC BIOSCIENCES UNVEILS SUPER IMMUNODEFICIENT MOUSE MODELS FOR ANTIBODY THERAPY ASSESSMENT

KUALA LUMPUR, Oct 25 (Bernama) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, has launched the FcResolv™ NOG portfolio.

The portfolio is the first and only super immunodeficient mouse models lacking residual murine Fc gamma receptors (FcγRs) known to confound results in antibody-based therapy studies.

According to a statement, murine FcγRs can cause false positives or false negatives, leading to incorrect conclusions and derail drug discovery.

FcResolv NOG models knock out these receptors for greater clarity in antibody-based drug studies, affording investigators greater confidence and more translatable data with fewer studies and fewer animals.

With applicability in oncology, immuno-oncology, and autoimmune disease, FcResolv NOG models are suitable for engrafting a wide range of human cells and tissues, including simultaneous human tumour engraftment and immune system humanisation.

FcResolv NOG models eliminate the false negatives that occur when an antibody-based therapeutic’s Fc domain interacts with murine FcγRs as well as the false positives that result when FcγRs trigger residual murine immune activity.

They also eliminate costly deconvolution steps otherwise needed to distinguish true drug efficacy from off-target effects mediated through the mouse immune system.

With more reliable answers, researchers can target their drug discovery investments more strategically and effectively.

-- BERNAMA